Moderna Inc. ($MRNA) Stock Forecast: Down 5.2% Today

What is Moderna Inc.?

Moderna (MRNA) is a biotechnology company recognized for its innovative mRNA technology, particularly in vaccine development. The biotech sector is currently viewed with optimism, highlighting advancements in oncology treatments and potential growth avenues.

Why is Moderna Inc. going down?

MRNA stock is down 5.2% on Jan 27, 2026 20:25

• Moderna (MRNA) underwent a period of bearish movement, potentially influenced by positive developments and growth projections of major competitors in the oncology market, including Merck (MRK), Oncolytics Biotech Inc. (ONCY), and other industry participants.
• Merck's (MRK) anticipated rise in earnings and revenues, progress in its oncology pipeline, and revised growth forecasts might have redirected investor attention from Moderna, leading to a decline in its stock performance.
• Analysts' call for enhanced clarity on long-term growth prospects at Merck, despite its notable performance, may have prompted investor apprehensions regarding Moderna's competitiveness and future growth trajectory in biotechnology.
• References to AI stocks presenting superior upside potential compared to Merck could have shifted investor focus towards alternative investment options, thereby contributing to the downward trend in Moderna's stock value.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

Merck (MRK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Merck (MRK) is expected to report a year-over-year increase in earnings and higher revenues for the quarter ended December 2025. The company's upcoming earnings report, due February 3, anticipates quarterly earnings of $2.04 per share and revenues of $16.19 billion. While the Zacks Earnings ESP suggests a potential positive surprise due to analysts becoming more bullish, Merck's Zacks Rank #4 makes a definitive prediction difficult.

https://finviz.com/news/288591/merck-mrk-earnings-expected-to-grow-what-to-know-ahead-of-next-weeks-release

Registration-Ready: How 2026’s Clinical Leaders Are Beating Cancer Benchmarks

The global oncology therapy market is projected to reach $668 billion by 2034, demanding registration-directed study designs that prioritize objective response rates and durability. Oncolytics Biotech Inc. (NASDAQ: ONCY) is strengthening its leadership and advancing pelareorep toward multiple registration-directed programs in gastrointestinal cancers, showing breakthrough efficacy data and securing FDA alignment for a Phase 3 pancreatic cancer study. Other key players like Moderna (NASDAQ: MRNA), Merck (NYSE: MRK), Vir Biotechnology (NASDAQ: VIR), and Coherus Oncology (NASDAQ: CHRS) are also making significant advancements in their respective oncology pipelines.

https://aijourn.com/registration-ready-how-2026s-clinical-leaders-are-beating-cancer-benchmarks/

GSK (NYSE:GSK) Stock Crosses Above 200 Day Moving Average - Time to Sell?

GSK (NYSE:GSK) shares recently crossed above their 200-day moving average, reaching $50.57, while the 200-day average stands at $43.95. Despite a strong recent earnings report and positive FY2025 guidance, analyst sentiment is cautious, with an average "Reduce" rating and a consensus target price of $44.13. Institutional investors and a major shareholder have recently made significant purchases of GSK stock.

https://www.marketbeat.com/instant-alerts/gsk-nysegsk-stock-crosses-above-200-day-moving-average-time-to-sell-2026-01-27/

Merck's (MRK) Quality is Clear, but Growth Visibility Matters, TD Cowen Notes

TD Cowen analyst Steve Scala raised Merck & Co., Inc. (MRK) price target to $120 from $100, maintaining a Hold rating while noting the company's strong quality. Despite this, Scala emphasized that Merck needs to demonstrate a clearer long-term growth outlook to stand out as a top pharma pick. Merck has responded by raising projections for new growth drivers, now expecting $70 billion in revenue by the mid-2030s, and shared positive results for its personalized cancer vaccine in combination with Keytruda.

https://finviz.com/news/287814/mercks-mrk-quality-is-clear-but-growth-visibility-matters-td-cowen-notes

Merck’s (MRK) Quality is Clear, but Growth Visibility Matters, TD Cowen Notes

TD Cowen analyst Steve Scala raised Merck & Co., Inc. (MRK) price target to $120 from $100 but maintained a Hold rating, citing the need for clearer long-term growth visibility despite Merck being a strong company. Merck recently increased its projections for new growth drivers, expecting around $70 billion in revenue by the mid-2030s, and shared positive five-year results for its personalized cancer vaccine combined with Keytruda for melanoma patients. The article also suggests that certain AI stocks may offer greater upside potential than MRK.

https://www.insidermonkey.com/blog/mercks-mrk-quality-is-clear-but-growth-visibility-matters-td-cowen-notes-1681868/

Trending Today

Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Up 5.8% Today

Centene Corporation ($CNC) Stock Forecast: Down 10.9% Today

Charter Communications Inc. ($CHTR) Stock Forecast: Down 5.1% Today

Elevance Health Inc. ($ELV) Stock Forecast: Down 14.2% Today

Quidelortho Corpoation ($QDEL) Stock Forecast: Down 5.3% Today

Plug Power Inc. ($PLUG) Stock Forecast: Up 5.0% Today

Synchrony Financial ($SYF) Stock Forecast: Down 6.0% Today

Moderna Inc. ($MRNA) Stock Forecast: Down 5.2% Today

United Parcel Service Inc. ($UPS) Stock Forecast: Up 0.8% Today

Clean Energy Fuels Corp. ($CLNE) Stock Forecast: Up 5.0% Today

Moderna Inc. Price History

27.00.2026 - MRNA Stock was up 6.0%

• MRNA stock experienced a bullish movement today.
• The positive market sentiment towards MRNA could be attributed to recent advancements in personalized cancer vaccines by another company, potentially boosting confidence in the biotech sector.
• Additionally, positive developments in the biotech industry, such as progress with a therapy for bladder cancer by another company, may have created a ripple effect of optimism among investors, benefiting companies like MRNA.
• Overall, the growing interest and potential breakthroughs in the biotech field seem to have contributed to the bullish movement in MRNA stock today.

27.00.2026 - MRNA Stock was down 5.2%

• Moderna (MRNA) underwent a period of bearish movement, potentially influenced by positive developments and growth projections of major competitors in the oncology market, including Merck (MRK), Oncolytics Biotech Inc. (ONCY), and other industry participants.
• Merck's (MRK) anticipated rise in earnings and revenues, progress in its oncology pipeline, and revised growth forecasts might have redirected investor attention from Moderna, leading to a decline in its stock performance.
• Analysts' call for enhanced clarity on long-term growth prospects at Merck, despite its notable performance, may have prompted investor apprehensions regarding Moderna's competitiveness and future growth trajectory in biotechnology.
• References to AI stocks presenting superior upside potential compared to Merck could have shifted investor focus towards alternative investment options, thereby contributing to the downward trend in Moderna's stock value.

23.00.2026 - MRNA Stock was down 10.9%

• The stock's decline may have been driven by profit-taking by investors following a recent 4% rally linked to positive five-year follow-up data for their mRNA cancer vaccine in collaboration with Merck.
• Concerns about potential competition or market positioning for Moderna in the oncology sector could have arisen with the amendment of the license agreement between Terns Pharmaceuticals and Hansoh for TERN-701 rights.
• Investor focus and capital might have been redirected towards the banking sector, particularly awaiting Itaú Unibanco's Q4 results, contributing to Moderna's downward trend.
• Despite the promising long-term prospects in oncology, external factors and short-term market dynamics possibly influenced the bearish performance today.

23.00.2026 - MRNA Stock was down 9.4%

• Moderna's stock saw a strong bearish movement possibly due to the announcement of limiting investment in new late-stage vaccine trials, reflecting concerns over achieving returns amidst regulatory hurdles and opposition in the US market.
• The groundbreaking five-year follow-up data for their mRNA cancer vaccine, which demonstrated positive results in high-risk melanoma patients, might have been overshadowed by the decision to curb vaccine trial investments, leading to investor uncertainty.
• The amended license agreement with Hansoh for TERN-701 by Terns Pharmaceuticals could have also impacted Moderna's stock negatively, as it potentially shifts focus and resources away from certain therapeutic products.
• Overall, the market may be reacting to the shifting priorities and strategies within Moderna, as it navigates challenges in the regulatory landscape and transitions towards personalized cancer treatments, impacting investor sentiment and stock performance.

23.00.2026 - MRNA Stock was down 10.7%

• The stock's decline could be attributed to profit-taking or concerns about vaccine distribution challenges.
• Positive updates on Lucid Group, Materion Corp, and Terns Pharmaceuticals might have shifted investor focus away from Moderna.
• Other companies' positive news and Itaú Unibanco's upcoming investor meeting could have added to the downward pressure on Moderna's stock.
• Despite today's bearish movement, Moderna's long-term outlook remains optimistic due to its crucial role in the pandemic response and continuous vaccine innovations.

21.00.2026 - MRNA Stock was up 16.9%

• Moderna's bullish movement today could be attributed to the broader positive sentiment in the cell and gene therapy market, driven by technological advancements and increasing demand for personalized medicine.
• Analysts' bullish outlook on Merck & Co. (MRK) and its potential acquisition of Revolution Medicines to strengthen its oncology pipeline may have positively influenced investor confidence in the biotech sector, including Moderna.
• The significant vaccine delivery licensing deal involving Pfizer and Novavax might have also boosted investor optimism in the biopharmaceutical industry, reflecting positively on Moderna's innovative approaches in vaccine development.
• Overall, the positive market movements in the biotech and pharmaceutical sectors, coupled with strategic advancements and collaborations within the industry, likely contributed to Moderna's strong bullish performance today.

21.00.2026 - MRNA Stock was up 5.5%

• Analysts are optimistic about Merck & Co. (MRK), with talk of a possible acquisition of Revolution Medicines enhancing positivity in the healthcare industry. This upbeat sentiment may have influenced the rise of Moderna's stock.
• The collaboration between Pfizer and Novavax on vaccine delivery technology showcases the competitive and ever-evolving landscape of the vaccine sector. This partnership potentially contributed to the favorable outlook towards Moderna.
• Moderna's strategic expansion into oncology, accompanied by encouraging data on its cancer therapy, has captured the attention of investors. The company's foray into areas beyond infectious disease vaccines might have played a part in its recent market upswing.
• Despite cautious views from BofA Securities on Moderna's stock value, the promising clinical results for its cancer vaccine Intismeran may have overshadowed apprehensions, leading to the positive momentum in the market.

21.00.2026 - MRNA Stock was up 11.6%

• The bullish movement in Moderna's stock today is influenced by the positive reception of the five-year follow-up data from its Phase IIb trial for a personalized mRNA-based cancer therapy, showing promising results for high-risk melanoma patients.
• Analyst sentiment toward Moderna remains optimistic, with BofA Securities recently raising its price target. Despite concerns about the stock valuation exceeding target levels and potential challenges in the oncology market, long-term confidence driven by strategic shifts and partnerships is boosting investor morale.
• Market movements within the biotechnology sector, such as news of acquisitions and licensing agreements by competitors like Merck and Novavax, may have also contributed to Moderna's positive momentum as investors recognize growth opportunities in the industry.
• Moderna's strategic focus on oncology, along with progress in its pipeline and favorable analyst outlook, positions the company well for future growth and innovation in the healthcare sector.

22.00.2026 - MRNA Stock was up 15.0%

• Moderna's bullish movement could be attributed to positive sentiment surrounding the company's COVID-19 vaccine sales and ongoing efforts in vaccine development.
• The market may be reacting favorably to the news of a global restructuring, potentially indicating investor confidence in companies adapting to optimize operations.
• Steady stock performance and positive outlook from an analyst firm could be contributing to a positive overall sentiment in the healthcare sector, benefiting companies like Moderna.
• A stock hitting a 52-week high and the positive analyst price target revisions could be boosting investor interest in the biotech sector, indirectly benefiting Moderna as well.

22.00.2026 - MRNA Stock was up 10.6%

• Moderna's bullish movement today could be attributed to positive sentiment surrounding the broader biotech sector and the company's ongoing efforts in vaccine development.
• The bullish market movement may also be influenced by the news of Bristol Myers partnering with Janux Therapeutics to develop novel tumor-activated therapeutics, highlighting the potential for innovative approaches in the healthcare industry.
• Additionally, the strong performance of other healthcare companies like Liquidia Technologies hitting an all-time high could have created a positive ripple effect in the sector, boosting investor confidence in Moderna's growth prospects.
• Overall, Moderna's bullish trend today seems to be driven by a combination of sector-wide optimism, positive developments in the healthcare industry, and potentially favorable market conditions for biotech companies.

22.00.2026 - MRNA Stock was up 12.0%

• The positive sentiment surrounding the efficacy and demand for Moderna's COVID-19 vaccine, as well as advancements in its pipeline for mRNA-based therapies, likely fueled the recent bullish movement.
• The collaboration between Janux Therapeutics and Bristol Myers Squibb could have played a role in boosting investor interest in biotech companies like Moderna.
• Abbott Laboratories' stock decline following revenue estimates miss may have indirectly benefited Moderna as investors potentially sought out companies with stronger growth potential.
• The selling of Merck & Co., Inc. shares by Bailard Inc. and other hedge funds may have shifted investments towards promising opportunities like Moderna, contributing to its bullish performance.

22.00.2026 - MRNA Stock was up 8.2%

• Moderna's stock surged by 4% following the groundbreaking five-year follow-up data for their mRNA cancer vaccine, showing a significant reduction in the risk of relapse or death in high-risk melanoma patients. This success not only boosted investor confidence in Moderna's technology but also solidified its position as a major player in oncology.
• The announcement of Moderna curbing investments in vaccine trials due to US backlash had a positive impact on the stock, with shares jumping by 10.16% in morning trading. This strategic shift towards personalized cancer treatments in response to regulatory hurdles demonstrates the company's adaptability and focus on long-term growth.
• The partnership between Bristol Myers Squibb and Janux Therapeutics in developing novel T cell engagers for solid tumors may have indirectly contributed to Moderna's bullish movement by highlighting the potential in oncology treatments, further fueling optimism in the biotech sector.
• Overall, Moderna's bullish market movement today can be attributed to its groundbreaking cancer vaccine data, strategic shift towards personalized treatments, and positive investor sentiment towards advancements in oncology therapies.